Wellington Management Group’s Zevra Therapeutics ZVRA Stock Holding History

Wellington Management Group’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.46M	Sell	156,417 -13,892	-8%	-$125K	﹤0.01%	1607
2025 Q4	$1.53M	Sell	170,309 -16,957	-9%	-$160K	﹤0.01%	1652
2025 Q3	$1.78M	Buy	187,266 +40,982	+28%	+$411K	﹤0.01%	1662
2025 Q2	$1.29M	Buy	146,284 +5,866	+4%	+$47.6K	﹤0.01%	1678
2025 Q1	$1.05M	Buy	+140,418	New	+$1.12M	﹤0.01%	1696
2024 Q2	–	Sell	-129,189	Closed	-$749K	–	1987
2024 Q1	$749K	Buy	+129,189	New	+$794K	﹤0.01%	1744
2016 Q2	–	Sell	-3,931	Closed	-$912K	–	2194
2016 Q1	$912K	Sell	3,931 -5,612	-59%	-$1.36M	﹤0.01%	1835
2015 Q4	$3.03M	Sell	9,543 -429	-4%	-$116K	﹤0.01%	1510
2015 Q3	$3.09M	Sell	9,972 -5,702	-36%	-$1.75M	﹤0.01%	1493
2015 Q2	$4.61M	Buy	+15,674	New	+$3.42M	﹤0.01%	1426

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group's ZVRA Position: Q1 2026 in Review

Wellington Management Group reduced its Zevra Therapeutics (ZVRA) stake by 8.2% in Q1 2026, selling an estimated $125K and leaving 156,417 shares worth $1.46M. The position accounts for ﹤0.01% of the portfolio, ranked #1607.

Wellington Management Group first reported a position in ZVRA in Q2 2015 and has held it in 10 quarters since. The position peaked at $4.61M in Q2 2015. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

Wellington Management Group held 156,417 shares of Zevra Therapeutics worth $1.46M as of Q1 2026.
Wellington Management Group sold 13,892 Zevra Therapeutics shares in Q1 2026, an estimated $125K.
Zevra Therapeutics made up ﹤0.01% of Wellington Management Group's portfolio in Q1 2026, its #1607 holding.
Wellington Management Group first reported a position in Zevra Therapeutics in Q2 2015 and has held it in 10 quarters since.
Wellington Management Group's Zevra Therapeutics position peaked at $4.61M in Q2 2015.
148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on Wellington Management Group's 13F filing for Q1 2026, filed 15 May 2026.